glp-1 drugs pharmaceutical companies 2025 Pipeline Update: August - Prime Therapeutics The Next Big Weight Loss

PMID: 24373234

doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade

The hormone-aware metabolic framework presented here is an educational model designed to organize current knowledge about menopause physiology, metabolic regulation, and GLP-1 therapy

GIP and GLP1 exert their effects by binding to their specific receptors, the GIP receptor (GIPR) and the GLP1 receptor (GLP1R), which belong to the Gprotein coupled receptor family

Retatrutide (Retara), approved in early 2026, is the newest